Vnitr Lek 2022, 68(7):E11-E16 | DOI: 10.36290/vnl.2022.100

Inflammatory markers in clinical practice

Štefan Sotak
I. interná klinika UPJŠ LF a UN LP v Košiciach

Inflammation is the general defense response of the body against various harmful irritations. Diagnosis of the inflammatory process and monitoring of its treatment is based on a combination of clinical and laboratory findings. Biochemical inflammatory markers usually serve to support the diagnosis of the infection, to monitor it, and to monitor the effectiveness of anti-infective treatment. The inflammatory marker should be selected according to the clinical condition with regard to the treachery and deficiencies of the markers, with knowledge of their dynamics and with regard to the length of the anamnesis. As an optimal procedure for detecting bacterial infection, it is recommended to screen for several acute phase proteins. The role of the physician is to determine when, under which circumstances, and which markers to have examined, with a view to ensuring that the patient is correctly diagnosed in time and receives appropriate treatment, and on the other hand, that he is not unnecessarily iatrogenized and that the medical facility does not lose money unnecessarily.

Keywords: inflammation, marker, CRP, PCT, IL 6.

Accepted: October 26, 2022; Published: October 31, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Sotak Š. Inflammatory markers in clinical practice. Vnitr Lek. 2022;68(7):E11-16. doi: 10.36290/vnl.2022.100.
Download citation

References

  1. Koporcová J. Súčasná laboratórna diagnostika zápalových stavov. inVitro. 2015;3(1):28-32.
  2. Kožíková K. Pozícia vyšetrenia CRP v indikácii ATB liečby v praxi všeobecného lekára. Košice: UNLP Košice 2011 [cit. 2020-10-25]. Dostupné z WWW: .
  3. Fadi FG, Szalai AJ. C‑Reactive Protein Gene Polymorphisms, C‑Reactive Protein Blood levels and Cardiovascular Disease Risk. JACC 2007;50(12):1115-1122. Go to original source... Go to PubMed...
  4. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic or unnecessary toys? Gut. 2006;55(3):426-431. Go to original source... Go to PubMed...
  5. Biasucci LM, Koenig W, Mair J et al. How to use C‑reactive protein in acute coronary care. EHJ. 2013;34(48):3687-3690.
  6. Nehring SM, Goyal A, Bansal P et al. C Reactive Protein, 2020. [cit. 2021-05-16]. Dostupné z WWW: .
  7. John JM, Bhatt DL. Emerging risk factors for atherosclerosis. Indian Heart J. 2007;59:28-37.
  8. Prasad K. C‑reactive Protein‑Lowering Agents. Cardiovasc Drug Rev. 2006;24(1):33-50. Go to original source... Go to PubMed...
  9. Seifert B. Diagnostika CRP. 2006 [cit. 2020-10-25]. Dostupné z WWW: .
  10. Liu HH, Guo JB, Geng Z. Procalcitonin: present and future. Ir J Med Sci. 2015;3(184):597-605. Go to original source... Go to PubMed...
  11. Zazula R, Průcha M, Spálený A et al. Prokalcitonin nejen v diferenciální diagnostice zánětlivé odpovědi organismu. Anest Intenziv Med. 2002; 2:86-91.
  12. Ban HJ, Ji SG, Chi SY et al. Usefulness of Serum procalcitonin in lung cancer patients with elevated serum C‑reactive protein level. BSJ. 2011;38(55):2803.
  13. Fournier T, Medjoubi‑N N Porquet D. Alpha-1-acid glycoprotein. Biochem Biophys Acta. 2000;1482(1-2):157-171. Go to original source... Go to PubMed...
  14. Ďurovcová E. CRP a iné markery zápalu v klinickej praxi. Interná med. 2019;19(9):341-346.
  15. Vlniešková K. Biochemické zápalové markery. NEWSLAB. 2016;7(1):62-64.
  16. Astigarraga I, Ollauri‑Ibanez C, Garcia‑Obregon S et al. Hyperferritinemia is a bad prognosis factor in COVID-19 patients and it is not specific for HLH in adults. PBC 2021;68(S1):covidwho-1107599.
  17. Taher MY, Davies, DM, Maher J. The role of the interleukin (IL)-6/IL-6 receptor axis in cancer. Biochem Soc Trans. 2018;46(6):1449-1462. Go to original source... Go to PubMed...
  18. Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute‑phase reactant. Eur J Biochem. 1999;265(2):501-523. Go to original source... Go to PubMed...
  19. Gregorová E, Klímová M. Laboratorní příručka. 2021. [cit. 2022-09-25]. Dostupné z WWW: .
  20. Malle E, De Beer FC. Human serum amyloid A (SAA) protein: a prominent acute‑phase reactant for clinical practice. Eur J Clin Invest. 1996;26:427-435. Go to original source... Go to PubMed...
  21. Yamada T. Serum amyloid A (SAA): a concise review of biology, assay methods and clinical usefulness. Clin Chem Lab Med. 1999;37:381-388. Go to original source... Go to PubMed...
  22. Hogarth MB, Gallimore R, Savage P et al. Acute phase proteins, C‑reactive protein and serum amyloid A protein, as prognostic markers in the elderly inpatient. Age Ageing. 1997;26:153-158. Go to original source... Go to PubMed...
  23. Jabor A, Franeková J, Kubíček Z. Principy interpretace laboratorních testů. 2nd ed. Grada Publishing, a. s.: Praha 2020. ISBN 9788027112722.
  24. Zavyalov VP, Hämäläinen‑Laanaya H, Korpela TK et al. Interferon‑inducible myxovirus resistance proteins: potential biomarkers for differentiating Viral from Bacterial Infections. Clin Chem. 2019;65(6):739-750. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.